However, HRD also renders BRCA1/2-mutant cancers sensitive to DNA-damaging agents, such as radiation3,4, platinum-based therapies5,6, and poly ADP-ribose polymerase (PARP) inhibitors7,8. The gene discussed is PARP1; the disease is cancer.